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Background: Disease modifying drugs help control the course of relapsing remitting multiple 
sclerosis (RRMS); however, good adherence is needed for long-term outcomes.
Objective: To evaluate patient adherence to treatment with subcutaneous interferon beta-1a 
using RebiSmart® and assess injection-site reactions and treatment satisfaction.
Methods: This prospective, single-arm, open-label, noninterventional multicenter Phase IV 
trial included disease modifying drug-experienced mobile patients with RRMS. Adherence 
was measured over 12 weeks. Items 13–23, 35, 37, and 38 of the Multiple Sclerosis Treatment 
Concerns Questionnaire (injection-site reactions and treatment satisfaction) were recorded at 
12 weeks.
Results: Sixty patients were recruited (mean age 43.7 [±SD 7.9] years; 83% female; mean years 
since multiple sclerosis diagnosis 6.7 [SD 4.5]). Adherence data were obtained in 54 patients only 
due to technical problems with six devices. Over 12 weeks, 89% (n=48) of patients had 90% 
adherence to treatment. Most patients experienced mild influenza-like symptoms and injection-
site reactions, and global side effects were minimal. Most patients (78%) rated the convenience 
as the most important aspect of the device, and most experienced no or mild pain.
Conclusion: RRMS patients treated with subcutaneous interferon beta-1a, administered with 
RebiSmart, demonstrated generally good adherence, and the treatment was generally well 
tolerated.
Keywords: adherence, multiple sclerosis, relapsing remitting MS, subcutaneous interferon 
beta-1a, RebiSmart, trial
Introduction
Multiple sclerosis (MS) is a chronic neurological disease mediated by an inflammatory 
process within the central nervous system and is the leading cause of disability among 
young adults.1 The exact cause of MS is unknown, although an autoimmune process 
has been implicated. Genetic susceptibility also has a role in disease initiation,2 in 
addition to, as yet unidentified, environmental factors.3
There is no cure for MS, but disease modifying drugs (DMDs) that can reduce 
relapse frequency and slow disability progression are available.4 Interferon (IFN) beta 
is a first-line DMD for relapsing remitting multiple sclerosis (RRMS). Its efficacy 
has been proved in several randomized controlled trials.5 However, the clinical and 
economic benefits of treatment with IFN beta, as with other DMDs, are dependent on 
good adherence to treatment.6–8
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Adherence is defined by the World Health Organiza-
tion as “the extent to which a person’s behavior – taking 
medication, following a diet, and/or executing lifestyle 
changes – corresponds with agreed recommendations from 
health care providers.”9 There are two main components to 
evaluating adherence: the maintenance of a drug regimen 
over time (persistence) and taking the medication according 
to the prescribed dose and schedule (compliance). As with 
treatments for other chronic diseases, low adherence to IFN 
beta treatment has been reported.10
Common side effects to IFN beta treatment, such as 
injection-site reactions and influenza-like symptoms, are 
known to lead to low adherence.10 Therefore, the implemen-
tation of measures to reduce these side effects may help to 
improve adherence to IFN beta treatment.
The use of an electronic injection device can reduce the 
severity of injection-site reactions and improve compliance 
of MS patients with IFN beta treatment.11–13 The RebiSmart® 
device, an electronic/electromechanical autoinjector, was 
designed to improve patient satisfaction when administering 
subcutaneous (sc) IFN beta-1a for the treatment of RRMS. 
The device enables patients to personalize the injection 
attributes (injection depth, speed, and duration), track their 
injection history, and provides patients and physicians with a 
tool to monitor patient adherence to subcutaneous interferon 
(sc IFN) beta-1a.
The aim of this study was to evaluate adherence to 
treatment with sc IFN beta-1a among patients with RRMS 
using the RebiSmart device over 12 weeks. The secondary 
objectives were to assess patient satisfaction and experience 
of factors that contribute to adherence.
Methods
research ethics and patient consent
Due to the nature of the study, the Norwegian (REK sør-øst B) 
and Danish (Videnskabsetiske komite Region Syddanmark) 
Regional Ethics Committees concluded that no approval was 
required. All patients provided written informed consent to 
participate in the study before any study-related activities 
were carried out.
study design
The ScanSmart study was a prospective, noninterventional 
observational Phase IV trial among patients with RRMS. One 
clinic in Norway and five clinics in Denmark participated 
in this study. The study is registered on ClinicalTrials.gov 
(NCT01125475).
Inclusion criteria were as follows: males and females 
aged between 18 and 65 years old, RRMS according to the 
revised McDonald Criteria (2005), an expanded disability 
status scale score (EDSS) of 6 at the screening visit, stable 
treatment (defined as treatment after a titration period) with 
sc IFN beta-1a 22/44 μg administered subcutaneously three 
times per week for a minimum of 4 weeks prior to inclusion 
using the RebiSmart electronic/electromechanical autoinjec-
tor, and previous treatment with DMDs for a minimum of 
6 months prior to the screening visit. Female patients were 
neither pregnant nor breastfeeding and were either postmeno-
pausal or surgically sterile or using a highly effective method 
of contraception for the duration of the study.
Patients were excluded from this trial if they had a relapse 
within 30 days prior to the first visit, had any contraindica-
tions to treatment with IFN beta-1a, or had any other signifi-
cant diseases that could influence the treatment.
Visits
Patients attended two scheduled visits: at screening or base-
line (day 0) and after 12 weeks or at the end of the treatment. 
Data obtained from the RebiSmart device were registered 
electronically at day 0 (visit 1) and after 12 weeks. Disease 
status (EDSS) was recorded in the case report form at the first 
visit. At the 12th week visit, the Multiple Sclerosis Treatment 
Concerns Questionnaire (MSTCQ) was distributed to the 
patients. The patients used a patient diary to register reasons 
for missed injections.
Treatment
RebiSmart administers sc IFN beta-1a from multidose car-
tridges. The device is designed to inject a fixed volume of 
0.50 mL per injection. Each multidose cartridge was prefilled 
with 1.5 mL of solution containing 66/132 μg IFN beta-1a. 
The cartridge was designed to deliver three individual doses 
of 0.5 mL solution for injection containing 22 or 44 μg sc 
IFN beta-1a, as per label and normal clinical practice. Treat-
ment was given for a period of 12 weeks after baseline and 
injections were administered at the same time of day on the 
same three days of the week, with at least 48 hours between 
each administration.
Primary endpoint
The primary endpoint was adherence to treatment in patients 
with RRMS using the RebiSmart device to self-inject sc IFN 
beta-1a in a multidose cartridge over 12 weeks.
secondary endpoints
The secondary endpoints were the occurrence of injection-
site reactions and patient satisfaction, determined from the 
MSTCQ. The MSTCQ is a 38-item questionnaire validated 
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to identify patient concerns with treatment with IFN beta; 
each item has a choice of five responses, except for item-38, 
which had a choice of six responses. We assessed patients’ 
responses on the injection-system satisfaction domain 
(items 13–23): items 13–16, influenza-like symptoms; items 
17–20, injection-site reactions; and items 21–23, global side 
effects; and 35, benefit; and 37, 38, pain-rating scale and 
pain-rating grade from the patient questionnaire at the end 
of 12 weeks.
In the MSTCQ form used in the study, the individual 
scores for items 13–23 were from 1 to 5. The scores for items 
13–20 were reverse coded, so that a higher score indicated a 
greater negative impact. The overall score for items 21–23 
ranged from 3 to 15, with the highest scores indicating the 
worst possible treatment satisfaction. The patient response 
to pain in the past 4 weeks was measured using a 100 mm 
visual analog scale, in which higher scores indicated greater 
pain. Reasons for missed injections were recorded in the 
patient treatment diary.
statistical analyses
No statistical hypotheses were planned, as this was a single-
arm study. The planned sample size of 100 patients is based 
on the estimate that 90% of patients treated for 12 weeks will 
be 80% adherent to treatment. This produces a 95% confi-
dence interval equal to the sample proportion plus or minus 
5%–6% when the estimated proportion is 90%.
The analysis of the primary endpoint was descrip-
tive, with the proportion of patients with adherence 
of 100%, 95%, 90%, 85%, 80%, and 75% to 
sc IFN beta-1a three times a week administered with the 
RebiSmart. Patients at the lower cutoff of 75% were regarded 
as truly nonadherent. Exact 95% CI was calculated using the 
Clopper–Pearson method.
Adherence was calculated as the number of injections 
administered, multiplied by 100 and divided by the expected 
number of injections (36 injections [100% adherence]). 
If treatment was terminated prematurely, the expected num-
ber of injections was calculated from the time on treatment 
in weeks, multiplied by the number of weeks on treatment. 
If a patient was lost to follow-up, no attempt was made to 
impute the adherence for this patient. If a RebiSmart device 
was lost or damaged, the patient was rescreened. If a patient 
completed the study but no injection data could be obtained 
from RebiSmart, the patient was excluded from the analysis. 
If RebiSmart data were lost for part of the treatment period 
two estimates of adherence were planned. In the first esti-
mate, it would be assumed that no injections were made in 
the part of the treatment period where the data were lost; in 
the second estimate, the days for which the data were lost 
would be excluded.
Assessment of factors contributing to adherence were ana-
lyzed on the proportion of patients with 80% and 100% 
adherence using logistic regression with demographic and 
safety variables (age, age at diagnosis, gender, disease dura-
tion, employment status, education, marital status, disease-
modifying therapy use, number of relapses, EDSS score at 
visit 1, influenza-like symptoms, injection-site reactions, 
global side effects, benefits of treatment, pain, dose, and 
number of relapses in the 2 years before screening) as covari-
ates. Covariates significant on a 5% level in the univariable 
logistic regression were planned to be included in the final 
multivariate models.
Analyses of the secondary endpoints were also descrip-
tive only. The secondary endpoints comprised the MSTCQ 
scores (±SD) of the items measured.
Data analyses were performed using SAS® software, 
version 9.2 (Cary, NC, USA), after importing data from 
a VieDoc™ database. All patient data were presented in 
separate listings. All analyses were based on data pooled 
across clinics.
Results
Patients
Due to recruitment difficulties, and in order to finalize the trial 
within reasonable timelines, the trial was stopped when a total 
of 60 subjects were screened and gave signed informed con-
sent to participate in the study. Demographic characteristics 
of the study population are presented in Table 1. MS history 
is shown in Table 2, and EDSS score at baseline is shown in 
Figure 1. There were no withdrawals from the study.
One patient was included in the study despite not having 
stable RebiSmart treatment in the last 4 weeks before base-
line. For six patients, all RebiSmart data were lost owing to 
the data not being recorded in the electronic case report form 
and, in accordance with the study protocol, these patients 
were not included in the calculation of the primary endpoint. 
Of these patients, one patient recorded one injection-site 
reaction as an adverse drug reaction; one patient recorded 
15 missed injections due to pain at injection site; one patient 
forgot to take one injection; and two patients also reported on-
going injection-site pain at the time of the last visit. For one 
additional patient, the RebiSmart data for the days between 
the baseline and visit 2 were lost due to a site error.
Primary endpoint
A total of 54 patients were included in the calculation of 
the primary efficacy endpoint. Of these patients, 51 (94%) 
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had adherence 75% (95% exact [Clopper–Pearson] 
CI: 85%–99%). Thirty-four (63%) patients had adherence 
of 100%. Only three (6%) patients had adherence 75% 
and could be defined as nonadherent according to the study 
protocol (Table 3). The proportion of patients at each level 
of adherence is shown in Figure 2. The reasons for missed 
injections were recorded in the patient diaries only at the 
centers in Denmark. Fifteen patients (27%) reported miss-
ing an injection. The most common patient-reported reason 
for missing an injection was forgetting to take the injection 
(11 patients [20%]).
secondary endpoints
The mean (±SD) MSTCQ subscale scores were 10.3 (3.6) 
for injection-site reactions and 7.4 (3.9) for influenza-like 
symptoms, out of a maximum of 20 for the worst possible 
outcomes, indicating that these side effects were mild. 
The global side effects subscale had a mean (SD) value 
of 5.0 (2.4), and all of the items in the global side effects 
subscale had a mean value 2, out of a maximum of 15 
for the worst possible outcome, indicating the best possible 
outcome for these assessments. The majority of patients 
(47 of 60 [78%]) stated that the overall convenience was 
the most important benefit of the injection system used in 
the study. The remainder rated fewer injection-site reactions 
(2 patients [3%]), less injection pain (7 patients [12%]), fewer 
influenza-like symptoms (1 patient [2%]) and fewer physical 
side effects (3 patients [5%]) as the most important benefits. 
Regression analysis did not identify any factors associated 
with 80% or 100% adherence.
The mean (±SD) MSTCQ score for pain (item 37) was 
25.3 (24.7), indicating that pain during the last 4 weeks was 
at the lower end of the scale. The mean (SD) pain score 
recorded during the last 4 weeks of the study was 1.9 (1.0), 
indicating that most of the patients had either no pain or mild 
pain from the injections, and no patient had a score higher 
than 4 (Distressing).
Discussion
Poor medication adherence is a major problem in the treat-
ment of MS. The Global Adherence project14 reported 
that in 2,566 patients enrolled at 176 sites in 22 countries, 
overall, 25% of patients taking DMDs for MS were not 
adherent (defined as missing at least one dose in the last 
4 weeks) to their prescribed treatment regimen (for sc IFN 
beta-1a, 73% of patients were nonadherent to their therapy). 
A review of patient adherence to DMDs reported adherence 
rates ranging from 41% to 88% regardless of the definition 
of adherence used, type of DMD agent, or study design.7 
Similar results were reported in a survey of 709 patients 
recruited from academic and community MS clinics in the 
USA, which showed that, overall, 37% of respondents were 
considered nonadherent (defined as missing 1 injection in 
the last 4 weeks).15 The level of adherence in the population 
reported here is consistent with these estimates (15 of 55 
Table 1 Patient demographics
Study center Total
Sønderberg Vejle Roskilde Glostrup Hillerød Sandvika
Patients, n 10 1 10 26 8 5 60
Female, n (%) 8 (80) 1 (100) 9 (90) 23 (88) 6 (75) 3 (60) 50 (83)
Age in years, mean (sD) 42.0 (5.0) 47.4 (nA) 45.7 (6.0) 44.6 (9.1) 41.8 (8.3) 40.3 (10.0) 43.7 (7.9)
employment status, n (%)
Full time 3 (30) 0 (0) 0 (0) 7 (27) 1 (13) 3 (60) 14 (23)
Part time 5 (50) 1 (100) 4 (40) 10 (38) 4 (50) 1 (20) 25 (42)
Unemployed 2 (20) 0 (0) 6 (60) 9 (35) 3 (38) 1 (20) 21 (35)
education status, n (%)
elementary 3 (30) 0 (0) 4 (40) 2 (8) 0 (0) 0 (0) 9 (15)
intermediate 6 (60) 0 (0) 6 (60) 18 (69) 7 (87.5) 3 (60) 40 (67)
higher 1 (10) 1 (100) 0 (0) 6 (23) 1 (12.5) 2 (40) 11 (18)
Marital status, n (%)
single/divorced 5 (50) 1 (100) 1 (10) 5 (19) 1 (13) 1 (20) 14 (23)
Married/living with partner 5 (50) 0 (0) 9 (90) 21 (81) 7 (87) 4 (80) 46 (77)
Table 2 Ms history
Mean value 
(±SD), years
Age at the time of first attack 34.5 (8.1)
Time since first attack 9.1 (5.8)
Age at the time of Ms diagnosis 37.0 (7.6)
Time since Ms diagnosis 6.7 (4.5)
Time since last clinical relapse 4.0 (3.3)
Abbreviation: Ms, multiple sclerosis.
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[27%] available patients recorded one or more missed dose 
over the 12 weeks).
The most common reported reasons for nonadherence 
were forgetting to administer the injection, cited by 50% of 
patients, followed by tired of taking injections (20%), pain at 
the injection site (12%), and injection anxiety (10%).14 Other 
studies have estimated on-treatment injection anxiety to range 
from 18% in one longitudinal study16 to 22% in the general 
population,13 and anxiety about injections before starting 
treatment was expressed by 40% of patients.16 While the use 
of electronic devices can help to relieve the physical and emo-
tional aspects contributing to lack of adherence by customizing 
injection parameters, more work will still be required to address 
the problem of patients forgetting to take their injection.17,18
Poor adherence to therapy can result in worse health 
outcomes.19 A retrospective analysis of 2,388 MS patients in 
the USA identified from a prescription claims database showed 
that patients who had a gap in treatment that was 90 days 
had a 1.9-fold higher risk of a severe relapse compared 
with a reference group with a gap in therapy of 0–10 days.19 
In a separate study comparing patients who were switched 
from IFN beta-1b three times per week to IFN beta-1a once 
per week,20,21 77% of patients who switched experienced a 
relapse compared with 21% of patients maintained on treat-
ment three times per week. Furthermore, the importance of 
adherence with long-term therapy in MS is illustrated by 
reports that patients discontinuing therapy had a significantly 
higher EDSS score at follow-up than those who remained on 
treatment.21 Similarly, the risk of disability progression and 
the worsening of relapse rate were reduced by about four- to 
fivefold in patients exposed to IFN-beta 1a for more than 
4 years compared with patients exposed for up to 2 years.22
Overall, these data suggest that a strategy aimed at help-
ing patients remember their dose, improving the comfort 
of injections, and making injection preparation convenient 
would help improve treatment compliance.23 Some studies12,13 
have demonstrated that the use of self-injection devices 
decreases the incidence of injection-site reactions and, most 
importantly, improves patient compliance with treatment. 
The incidence of injection-site reactions can be reduced 
with correct injection technique and by the use of injection 
devices.17,24 However, to date, there has not been a device with 
the functionality to track injections to provide an accurate 
estimate of adherence that can be shared between the MS 
patient and healthcare provider.
The RebiSmart device was developed with the aim of 
improving adherence by incorporating the following key fea-
tures: convenience offered by the delivery of multiple fixed 
doses; a reminder system via the injection log; the ability for 
patients to customize the settings for injection speed, depth, 
and duration; detailed step-by-step instructions; and the facility 
to monitor treatment adherence by tracking of injection history, 
which can be downloaded, to inform healthcare professionals 
and motivate patients regarding the level of adherence.
Table 3 Adherence to rebismart®
Adherence Patients, N (%; exact Clopper– 
Pearson 95% CI)
75% 51 (94; 85–99)
80% 50 (93; 82–98)
85% 49 (91; 80–97)
90% 47 (87; 75–95)
95% 41 (76; 62–87)
100% 34 (63; 49–76)
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Figure 1 eDss score distribution at baseline.
Abbreviation: eDss, expanded disability status scale.
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Of the patients using the RebiSmart device, almost 80% 
of patients completed more than 90% of the planned injections 
over the 12-week period. This high level of adherence with an 
electronic device is in agreement with the results from other 
studies.6,25,26 Furthermore, although injection-site reactions 
and influenza-like symptoms were not completely reduced, 
the treatment was generally well tolerated, and a high pro-
portion of patients expressed satisfaction with the RebiSmart 
device, largely driven by the convenience it provides. This 
may indicate that convenience is a key factor in patient adher-
ence to DMDs that could warrant further investigation.
Although the observation period reported here is short, 
these data indicate that good adherence can be achieved when 
patients use RebiSmart. In addition to the short time duration, 
there are other limitations to this study. Difficulty in recruiting 
patients meant that we were unable to include the estimated 100 
patients, and many of the patients included (98%) had used the 
RebiSmart device prior to enrolment in the study, therefore, 
adherence to this device may be better in this group compared 
with patients with MS in general. Furthermore, as there was 
no comparator in this single-arm, open-label study, direct 
comparisons with other injectable DMDs are not possible.
Our results show that the use of the RebiSmart device 
is potentially important to accurately monitor adherence 
to treatment in patients with RRMS and may contribute to 
increased adherence. Almost 80% of patients stated that 
“overall convenience” was the most important benefit of 
the injection system.
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